1
|
Incorvaia L, De Biase D, Nannini M, Fumagalli E, Vincenzi B, De Luca I, Brando C, Perez A, Pantaleo MA, Gasperoni S, D’Ambrosio L, Grignani G, Maloberti T, Pedone E, Bazan Russo TD, Mazzocca A, Algeri L, Dimino A, Barraco N, Serino R, Gristina V, Galvano A, Bazan V, Russo A, Badalamenti G. KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study. Oncologist 2024; 29:e141-e151. [PMID: 37463014 PMCID: PMC10769785 DOI: 10.1093/oncolo/oyad206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 06/09/2023] [Indexed: 01/07/2024] Open
Abstract
BACKGROUND The patient selection for optimal adjuvant therapy in gastrointestinal stromal tumors (GISTs) is provided by nomogram based on tumor size, mitotic index, tumor location, and tumor rupture. Although mutational status is not currently used to risk assessment, tumor genotype showed a prognostic influence on natural history and tumor relapse. Innovative measures, such as KIT/PDGFRA-mutant-specific variant allele frequency (VAF) levels detection from next-generation sequencing (NGS), may act as a surrogate of tumor burden and correlate with prognosis and overall survival of patients with GIST, helping the choice for adjuvant treatment. PATIENTS AND METHODS This was a multicenter, hospital-based, retrospective/prospective cohort study to investigate the prognostic role of KIT or PDGFRA-VAF of GIST in patients with radically resected localized disease. In the current manuscript, we present the results from the retrospective phase of the study. RESULTS Two-hundred (200) patients with GIST between 2015 and 2022 afferent to 6 Italian Oncologic Centers in the EURACAN Network were included in the study. The receiver operating characteristic (ROC) curves analysis was used to classify "low" vs. "high" VAF values, further normalized on neoplastic cellularity (nVAF). When RFS between the low and high nVAF groups were compared, patients with GIST with KIT/PDGFRA nVAF > 50% showed less favorable RFS than patients in the group of nVAF ≤ 50% (2-year RFS, 72.6% vs. 93%, respectively; P = .003). The multivariable Cox regression model confirmed these results. In the homogeneous sub-population of intermediate-risk, patients with KIT-mutated GIST, the presence of nVAF >50% was statistically associated with higher disease recurrence. CONCLUSION In our study, we demonstrated that higher nVAF levels were independent predictors of GIST prognosis and survival in localized GIST patients with tumors harboring KIT or PDGFRA mutations. In the cohort of intermediate-risk patients, nVAF could be helpful to improve prognostication and the use of adjuvant imatinib.
Collapse
Affiliation(s)
- Lorena Incorvaia
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Dario De Biase
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
- Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Margherita Nannini
- Department of Experimental, Diagnostic and Specialized Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Elena Fumagalli
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Bruno Vincenzi
- Department of Medical Oncology, Campus Biomedico University of Rome, Rome, Italy
| | - Ida De Luca
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Chiara Brando
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Alessandro Perez
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Maria A Pantaleo
- Department of Experimental, Diagnostic and Specialized Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Silvia Gasperoni
- Department of Oncology and Robotic Surgery, Translational Oncology Unit, University Hospital Careggi, Firenze, Italy
| | - Lorenzo D’Ambrosio
- Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS, Candiolo, TO, Italy
| | - Giovanni Grignani
- Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS, Candiolo, TO, Italy
| | - Thais Maloberti
- Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
| | - Erika Pedone
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Tancredi Didier Bazan Russo
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Alessandro Mazzocca
- Department of Medical Oncology, Campus Biomedico University of Rome, Rome, Italy
| | - Laura Algeri
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Alessandra Dimino
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Nadia Barraco
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Roberta Serino
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Valerio Gristina
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Antonio Galvano
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Viviana Bazan
- Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Antonio Russo
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Giuseppe Badalamenti
- Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| |
Collapse
|
2
|
Cappello G, Giannini V, Cannella R, Tabone E, Ambrosini I, Molea F, Damiani N, Landolfi I, Serra G, Porrello G, Gozzo C, Incorvaia L, Badalamenti G, Grignani G, Merlini A, D’Ambrosio L, Bartolotta TV, Regge D. A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST). Eur J Radiol Open 2023; 11:100505. [PMID: 37484979 PMCID: PMC10362081 DOI: 10.1016/j.ejro.2023.100505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/25/2023] Open
Abstract
Objectives To develop a mutation-based radiomics signature to predict response to imatinib in Gastrointestinal Stromal Tumors (GISTs). Methods Eighty-two patients with GIST were enrolled in this retrospective study, including 52 patients from one center that were used to develop the model, and 30 patients from a second center to validate it. Reference standard was the mutational status of tyrosine-protein kinase (KIT) and platelet-derived growth factor α (PDGFRA). Patients were dichotomized in imatinib sensitive (group 0 - mutation in KIT or PDGFRA, different from exon 18-D842V), and imatinib non-responsive (group 1 - PDGFRA exon 18-D842V mutation or absence of mutation in KIT/PDGFRA). Initially, 107 texture features were extracted from the tumor masks of baseline computed tomography scans. Different machine learning methods were then implemented to select the best combination of features for the development of the radiomics signature. Results The best performance was obtained with the 5 features selected by the ANOVA model and the Bayes classifier, using a threshold of 0.36. With this setting the radiomics signature had an accuracy and precision for sensitive patients of 82 % (95 % CI:60-95) and 90 % (95 % CI:73-97), respectively. Conversely, a precision of 80 % (95 % CI:34-97) was obtained in non-responsive patients using a threshold of 0.9. Indeed, with the latter setting 4 patients out of 5 were correctly predicted as non-responders. Conclusions The results are a first step towards using radiomics to improve the management of patients with GIST, especially when tumor tissue is unavailable for molecular analysis or when molecular profiling is inconclusive.
Collapse
Affiliation(s)
- Giovanni Cappello
- Department of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, Turin 10060, Italy
| | - Valentina Giannini
- Department of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, Turin 10060, Italy
- Department of Surgical Sciences, University of Turin, Turin 10124, Italy
| | - Roberto Cannella
- Section of Radiology - Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Via del Vespro 129, Palermo 90127, Italy
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy
| | - Emanuele Tabone
- Department of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, Turin 10060, Italy
| | - Ilaria Ambrosini
- Department of Translational Research, Academic Radiology, University of Pisa, Italy
- Previously at Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, Turin 10060, Italy
| | - Francesca Molea
- Department of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, Turin 10060, Italy
- Department of Surgical Sciences, University of Turin, Turin 10124, Italy
| | - Nicolò Damiani
- Department of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, Turin 10060, Italy
- Department of Surgical Sciences, University of Turin, Turin 10124, Italy
| | - Ilenia Landolfi
- Department of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, Turin 10060, Italy
- Department of Surgical Sciences, University of Turin, Turin 10124, Italy
| | - Giovanni Serra
- Department of Surgical Sciences, University of Turin, Turin 10124, Italy
| | - Giorgia Porrello
- Section of Radiology - Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Via del Vespro 129, Palermo 90127, Italy
| | - Cecilia Gozzo
- Department of Radiology, Humanitas, Istituto Clinico Catanese, Catania, Italy
| | - Lorena Incorvaia
- Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Giuseppe Badalamenti
- Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy
| | - Giovanni Grignani
- Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, Turin 10060, Italy
| | - Alessandra Merlini
- Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, Turin 10060, Italy
- Department of Oncology, University of Turin, Regione Gonzole 10, Orbassano, Turin 10043, Italy
| | - Lorenzo D’Ambrosio
- Department of Oncology, University of Turin, Regione Gonzole 10, Orbassano, Turin 10043, Italy
- Medical Oncology, University Hospital S. Luigi Gonzaga, regione Gonzole 10, Orbassano, Turin 10043, Italy
- Previously at Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, Turin 10060, Italy
| | - Tommaso Vincenzo Bartolotta
- Section of Radiology - Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Via del Vespro 129, Palermo 90127, Italy
- Department of Radiology, Fondazione Istituto Giuseppe Giglio, Ct.da Pietrapollastra, Via Pisciotto, Cefalù, Palermo 90015, Italy
| | - Daniele Regge
- Department of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, Turin 10060, Italy
- Department of Surgical Sciences, University of Turin, Turin 10124, Italy
| |
Collapse
|
3
|
D’Ambrosio L, Fumagalli E, De Pas TM, Nannini M, Bertuzzi A, Carpano S, Boglione A, Buonadonna A, Comandini D, Gasperoni S, Vincenzi B, Brunello A, Badalamenti G, Maccaroni E, Baldi GG, Merlini A, Mogavero A, Ligorio F, Pennacchioli E, Conforti F, Manessi G, Aliberti S, Tolomeo F, Fiore M, Sbaraglia M, Dei Tos AP, Stacchiotti S, Pantaleo MA, Gronchi A, Grignani G. Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group. JAMA Netw Open 2023; 6:e2341522. [PMID: 37930700 PMCID: PMC10628737 DOI: 10.1001/jamanetworkopen.2023.41522] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Accepted: 09/25/2023] [Indexed: 11/07/2023] Open
Abstract
Importance Gastrointestinal stromal tumor (GIST) follow-up is recommended by international guidelines, but data on the role of follow-up in patients with low relapse risk are missing. For these patients, the potential benefit of anticipating recurrence detection should be weighed against psychological burden and radiologic examination loads in terms of costs and radiation exposure. Objective To evaluate the outcomes of guideline-based follow-up in low-risk GIST. Design, Setting, and Participants This multi-institutional retrospective cohort study involving Italian Sarcoma Group reference institutions evaluated patients with GIST who underwent surgery between January 2001 and June 2019. Median follow-up time was 69.2 months. Data analysis was performed from December 15, 2022, to March 20, 2023. Patients with GIST at low risk according to Armed Forces Institute of Pathology criteria were included provided adequate clinical information was available: primary site, size, mitotic index, surgical margins, and 2 or more years of follow-up. Exposures All patients underwent follow-up according to European Society for Medical Oncology (ESMO) guidelines. Main Outcomes and Measures The primary outcome was the number of tests needed to identify a relapse according to ESMO guidelines follow-up plan. Secondary outcomes included relapse rate, relapse timing, disease-free survival (DFS), overall survival (OS), GIST-specific survival (GIST-SS), postrelapse OS, secondary tumor rates, and theoretical ionizing radiation exposure. An exploratory end point, new follow-up schedule proposal for patients with low-risk GIST according to the observed results, was also assessed. Results A total of 737 patients (377 men [51.2%]; median age at diagnosis, 63 [range, 18-86] years) with low-risk GIST were included. Estimated 5-year survival rates were 95.5% for DFS, 99.8% for GIST-SS, and 96.1% for OS. Estimated 10-year survival rates were 93.4% for DFS, 98.1% for GIST-SS, and 91.0% for OS. Forty-two patients (5.7%) experienced disease relapse during follow-up (9 local, 31 distant, 2 both), of which 9 were detected after 10 or more years. This translated into approximately 1 relapse detected for every 170 computed tomography scans performed, with a median radiation exposure of 80 (IQR, 32-112) mSv per patient. Nongastric primary tumor (hazard ratio [HR], 2.09; 95% CI, 1.14-3.83; P = .02), and KIT mutation (HR, 2.77; 95% CI, 1.05-7.27; P = .04) were associated with a higher risk of relapse. Second tumors affected 187 of 737 patients (25%), of which 56 were detected during follow-up and represented the primary cause of death in these patients. Conclusions and Relevance In this cohort study on patients affected by low-risk GISTs, the risk of relapse was low despite a follow-up across 10 or more years. These data suggest the need to revise follow-up schedules to reduce the anxiety, costs, and radiation exposure of currently recommended follow-up strategy.
Collapse
Affiliation(s)
- Lorenzo D’Ambrosio
- Department of Medical Oncology, University of Turin, Turin, Italy
- San Luigi Gonzaga University Hospital, Orbassano, Italy
| | - Elena Fumagalli
- Medical Oncology Unit 2, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - Tommaso Martino De Pas
- Medical Oncology Division, Cliniche Humanitas Gavazzeni, Bergamo, Italy
- Previously at Unit of Sarcomas and Thymomas, European Institute of Oncology, Milan, Italy
| | - Margherita Nannini
- Oncology Unit. Department of Medical and Surgical Sciences, University of Bologna, 40138, Bologna, Italy
| | - Alexia Bertuzzi
- Medical Oncology, Humanitas Cancer Center, Rozzano (MI), Italy
| | - Silvia Carpano
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | | | - Angela Buonadonna
- Sarcoma and gastrointestinal tumors Unit, Centro di Riferimento Oncologico, Aviano, Italy
| | - Danila Comandini
- Medical Oncology 1, Ospedale Policlinico San Martino, University of Genova, Genova, Italy
| | - Silvia Gasperoni
- Clinical Oncology Unit, Oncology Department and Robotic Surgery, AOU Careggi, Florence, Italy
| | - Bruno Vincenzi
- Medical Oncology, Università Campus Bio-Medico, Rome, Italy
| | | | - Giuseppe Badalamenti
- Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Elena Maccaroni
- Department of Oncology, Azienda Ospedaliero-Universitaria delle Marche, 60126 Ancona, Italy
| | | | - Alessandra Merlini
- Department of Medical Oncology, University of Turin, Turin, Italy
- Sarcoma Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy
| | - Andrea Mogavero
- Department of Medical Oncology, University of Turin, Turin, Italy
- Sarcoma Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy
| | - Francesca Ligorio
- Medical Oncology Unit 2, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | | | - Fabio Conforti
- Medical Oncology Division, Cliniche Humanitas Gavazzeni, Bergamo, Italy
- Previously at Unit of Sarcomas and Thymomas, European Institute of Oncology, Milan, Italy
| | - Giulia Manessi
- Department of Medical Oncology, University of Turin, Turin, Italy
- Sarcoma Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy
| | - Sandra Aliberti
- Sarcoma Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy
| | - Francesco Tolomeo
- Sarcoma Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy
| | - Marco Fiore
- Sarcoma Service, Surgical Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - Marta Sbaraglia
- Department of Medicine, University of Padua School of Medicine, Padua, Italy
| | | | | | - Maria Abbondanza Pantaleo
- Oncology Unit. Department of Medical and Surgical Sciences, University of Bologna, 40138, Bologna, Italy
| | - Alessandro Gronchi
- Sarcoma Service, Surgical Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - Giovanni Grignani
- Sarcoma Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy
- Medical Oncology 2, AOU Città della Salute e della Scienza di Torino, Turin, Italy
| |
Collapse
|
4
|
Butera A, Agostini M, Cassandri M, De Nicola F, Fanciulli M, D’Ambrosio L, Falasca L, Nardacci R, Wang L, Piacentini M, Knight RA, Jia W, Sun Q, Shi Y, Wang Y, Candi E, Melino G. ZFP750 affects the cutaneous barrier through regulating lipid metabolism. Sci Adv 2023; 9:eadg5423. [PMID: 37115925 PMCID: PMC10146900 DOI: 10.1126/sciadv.adg5423] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
An essential function of the epidermis is to provide a physical barrier that prevents the loss of water. Essential mediators of this barrier function include ceramides, cholesterol, and very long chain fatty acids, and their alteration causes human pathologies, including psoriasis and atopic dermatitis. A frameshift mutation in the human ZNF750 gene, which encodes a zinc finger transcription factor, has been shown to cause a seborrhea-like dermatitis. Here, we show that genetic deletion of the mouse homolog ZFP750 results in loss of epidermal barrier function, which is associated with a substantial reduction of ceramides, nonpolar lipids. The alteration of epidermal lipid homeostasis is directly linked to the transcriptional activity of ZFP750. ZFP750 directly and/or indirectly regulates the expression of crucial enzymes primarily involved in the biosynthesis of ceramides. Overall, our study identifies the transcription factor ZFP750 as a master regulator epidermal homeostasis through lipid biosynthesis and thus contributing to our understanding of the pathogenesis of several human skin diseases.
Collapse
Affiliation(s)
- Alessio Butera
- Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”, 00133 Rome, Italy
| | - Massimiliano Agostini
- Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”, 00133 Rome, Italy
| | - Matteo Cassandri
- Department of Oncohematology, Bambino Gesù Children’s Hospital, 00146 Rome, Italy
| | - Francesca De Nicola
- Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Maurizio Fanciulli
- Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Lorenzo D’Ambrosio
- Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Laura Falasca
- Laboratory of Electron Microscopy, National Institute for Infectious Diseases “L. Spallanzani,” IRCCS, Rome Italy
| | - Roberta Nardacci
- Laboratory of Electron Microscopy, National Institute for Infectious Diseases “L. Spallanzani,” IRCCS, Rome Italy
- Departmental Faculty of Medicine and Surgery, Saint Camillus International University of Health Sciences (UniCamillus), Rome, Italy
| | - Lu Wang
- University of Hawaii Cancer Center, Honolulu, HI 96813, USA
| | - Mauro Piacentini
- Laboratory of Electron Microscopy, National Institute for Infectious Diseases “L. Spallanzani,” IRCCS, Rome Italy
| | - Richard A. Knight
- Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”, 00133 Rome, Italy
| | - Wei Jia
- University of Hawaii Cancer Center, Honolulu, HI 96813, USA
- School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China
| | - Qiang Sun
- Laboratory of Cell Engineering, Institute of Biotechnology, Research Unit of Cell Death Mechanism, 2021RU008, Chinese Academy of Medical Science, 20 Dongda Street, Beijing, 100071, China
| | - Yufang Shi
- The Third Affiliated Hospital of Soochow University, State Key Laboratory of Radiation Medicine and Protection, Institutes for Translational Medicine, Soochow University, Suzhou 215123, China
| | - Ying Wang
- CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences/Shanghai Jiao Tong University School of Medicine, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
| | - Eleonora Candi
- Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”, 00133 Rome, Italy
- IDI-IRCCS, via Monti di Creta, 106, 00166 Rome, Italy
| | - Gerry Melino
- Department of Experimental Medicine, TOR, University of Rome “Tor Vergata”, 00133 Rome, Italy
- Corresponding author.
| |
Collapse
|
5
|
Rotolo R, Leuci V, Donini C, Galvagno F, Massa A, De Santis MC, Peirone S, Medico G, Sanlorenzo M, Vujic I, Gammaitoni L, Basiricò M, Righi L, Riganti C, Salaroglio IC, Napoli F, Tabbò F, Mariniello A, Vigna E, Modica C, D’Ambrosio L, Grignani G, Taulli R, Hirsch E, Cereda M, Aglietta M, Scagliotti GV, Novello S, Bironzo P, Sangiolo D. Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells. Clin Cancer Res 2023; 29:621-634. [PMID: 36165915 PMCID: PMC9890136 DOI: 10.1158/1078-0432.ccr-22-0761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2022] [Revised: 08/18/2022] [Accepted: 09/16/2022] [Indexed: 02/05/2023]
Abstract
PURPOSE Antibodies against the lymphocyte PD-1 (aPD-1) receptor are cornerstone agents for advanced non-small cell lung cancer (NSCLC), based on their ability to restore the exhausted antitumor immune response. Our study reports a novel, lymphocyte-independent, therapeutic activity of aPD-1 against NSCLC, blocking the tumor-intrinsic PD-1 receptors on chemoresistant cells. EXPERIMENTAL DESIGN PD-1 in NSCLC cells was explored in vitro at baseline, including stem-like pneumospheres, and following treatment with cisplatin both at transcriptional and protein levels. PD-1 signaling and RNA sequencing were assessed. The lymphocyte-independent antitumor activity of aPD-1 was explored in vitro, by PD-1 blockade and stimulation with soluble ligand (PD-L1s), and in vivo within NSCLC xenograft models. RESULTS We showed the existence of PD-1+ NSCLC cell subsets in cell lines and large in silico datasets (Cancer Cell Line Encyclopedia and The Cancer Genome Atlas). Cisplatin significantly increased PD-1 expression on chemo-surviving NSCLC cells (2.5-fold P = 0.0014), while the sequential treatment with anti-PD-1 Ab impaired their recovery after chemotherapy. PD-1 was found to be associated with tumor stemness features. PD-1 expression was enhanced in NSCLC stem-like pneumospheres (P < 0.0001), significantly promoted by stimulation with soluble PD-L1 (+27% ± 4, P < 0.0001) and inhibited by PD-1 blockade (-30% ± 3, P < 0.0001). The intravenous monotherapy with anti-PD-1 significantly inhibited tumor growth of NSCLC xenografts in immunodeficient mice, without the contribution of the immune system, and delayed the occurrence of chemoresistance when combined with cisplatin. CONCLUSIONS We report first evidence of a novel lymphocyte-independent activity of anti-PD-1 antibodies in NSCLC, capable of inhibiting chemo-surviving NSCLC cells and exploitable to contrast disease relapses following chemotherapy. See related commentary by Augustin et al., p. 505.
Collapse
Affiliation(s)
- Ramona Rotolo
- Department of Oncology, University of Turin, Torino, Italy
- Candiolo Cancer Institute FPO – IRCCS, Candiolo (Torino), Italy
| | - Valeria Leuci
- Candiolo Cancer Institute FPO – IRCCS, Candiolo (Torino), Italy
| | - Chiara Donini
- Department of Oncology, University of Turin, Torino, Italy
- Candiolo Cancer Institute FPO – IRCCS, Candiolo (Torino), Italy
| | - Federica Galvagno
- Department of Oncology, University of Turin, Torino, Italy
- Candiolo Cancer Institute FPO – IRCCS, Candiolo (Torino), Italy
| | - Annamaria Massa
- Department of Oncology, University of Turin, Torino, Italy
- Candiolo Cancer Institute FPO – IRCCS, Candiolo (Torino), Italy
| | - Maria Chiara De Santis
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - Serena Peirone
- Department of Biosciences, University of Milan, Milan, Italy
- Italian Institute for Genomic Medicine, c/o IRCCS, Candiolo (Torino), Italy
| | | | - Martina Sanlorenzo
- Comprehensive Cancer Center, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
| | - Igor Vujic
- The Rudolfstiftung Hospital, Vienna, Austria
- Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria
| | | | - Marco Basiricò
- Candiolo Cancer Institute FPO – IRCCS, Candiolo (Torino), Italy
| | - Luisella Righi
- Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano (TO), Italy
| | - Chiara Riganti
- Department of Oncology, University of Turin, Torino, Italy
| | | | - Francesca Napoli
- Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano (TO), Italy
| | - Fabrizio Tabbò
- Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano (TO), Italy
| | - Annapaola Mariniello
- Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano (TO), Italy
| | - Elisa Vigna
- Department of Oncology, University of Turin, Torino, Italy
- Candiolo Cancer Institute FPO – IRCCS, Candiolo (Torino), Italy
| | - Chiara Modica
- Candiolo Cancer Institute FPO – IRCCS, Candiolo (Torino), Italy
- Department of Surgical, Oncological and Stomatological Sciences (DICHIRONS), University of Palermo, Palermo, Italy
| | - Lorenzo D’Ambrosio
- Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano (TO), Italy
| | | | - Riccardo Taulli
- Department of Oncology, University of Turin, Torino, Italy
- Center for Experimental Research and Medical Studies (CeRMS), City of Health and Science University Hospital di Torino, Torino, Italy
| | - Emilio Hirsch
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - Matteo Cereda
- Department of Biosciences, University of Milan, Milan, Italy
- Italian Institute for Genomic Medicine, c/o IRCCS, Candiolo (Torino), Italy
| | - Massimo Aglietta
- Department of Oncology, University of Turin, Torino, Italy
- Candiolo Cancer Institute FPO – IRCCS, Candiolo (Torino), Italy
| | | | - Silvia Novello
- Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano (TO), Italy
| | - Paolo Bironzo
- Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano (TO), Italy
| | - Dario Sangiolo
- Department of Oncology, University of Turin, Torino, Italy
- Candiolo Cancer Institute FPO – IRCCS, Candiolo (Torino), Italy
| |
Collapse
|
6
|
Merlini A, Pavese V, Manessi G, Rabino M, Tolomeo F, Aliberti S, D’Ambrosio L, Grignani G. Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions. Front Oncol 2023; 13:1095219. [PMID: 36741019 PMCID: PMC9893281 DOI: 10.3389/fonc.2023.1095219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Accepted: 01/03/2023] [Indexed: 01/20/2023] Open
Abstract
Effective treatment of advanced/metastatic bone and soft tissue sarcomas still represents an unmet medical need. Recent advances in targeted therapies have highlighted the potential of cyclin-dependent kinases (CDK) inhibitors in several cancer types, including sarcomas. CDKs are master regulators of the cell cycle; their dysregulation is listed among the "hallmarks of cancer" and sarcomas are no exception to the rule. In this review, we report both the molecular basis, and the potential therapeutic implications for the use of CDK inhibitors in sarcoma treatment. What is more, we describe and discuss the possibility and biological rationale for combination therapies with conventional treatments, target therapy and immunotherapy, highlighting potential avenues for future research to integrate CDK inhibition in sarcoma treatment.
Collapse
Affiliation(s)
- Alessandra Merlini
- Candiolo Cancer Institute, IRCCS-FPO, Turin, Italy,Department of Oncology, University of Turin, Turin, Italy
| | - Valeria Pavese
- Department of Oncology, University of Turin, Turin, Italy
| | - Giulia Manessi
- Department of Oncology, University of Turin, Turin, Italy
| | - Martina Rabino
- Department of Oncology, University of Turin, Turin, Italy
| | | | | | - Lorenzo D’Ambrosio
- Department of Oncology, University of Turin, Turin, Italy,Medical Oncology, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Turin, Italy,*Correspondence: Lorenzo D’Ambrosio,
| | | |
Collapse
|
7
|
Porciello N, Franzese O, D’Ambrosio L, Palermo B, Nisticò P. T-cell repertoire diversity: friend or foe for protective antitumor response? J Exp Clin Cancer Res 2022; 41:356. [PMID: 36550555 PMCID: PMC9773533 DOI: 10.1186/s13046-022-02566-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Accepted: 12/09/2022] [Indexed: 12/24/2022]
Abstract
Profiling the T-Cell Receptor (TCR) repertoire is establishing as a potent approach to investigate autologous and treatment-induced antitumor immune response. Technical and computational breakthroughs, including high throughput next-generation sequencing (NGS) approaches and spatial transcriptomics, are providing unprecedented insight into the mechanisms underlying antitumor immunity. A precise spatiotemporal variation of T-cell repertoire, which dynamically mirrors the functional state of the evolving host-cancer interaction, allows the tracking of the T-cell populations at play, and may identify the key cells responsible for tumor eradication, the evaluation of minimal residual disease and the identification of biomarkers of response to immunotherapy. In this review we will discuss the relationship between global metrics characterizing the TCR repertoire such as T-cell clonality and diversity and the resultant functional responses. In particular, we will explore how specific TCR repertoires in cancer patients can be predictive of prognosis or response to therapy and in particular how a given TCR re-arrangement, following immunotherapy, can predict a specific clinical outcome. Finally, we will examine current improvements in terms of T-cell sequencing, discussing advantages and challenges of current methodologies.
Collapse
Affiliation(s)
- Nicla Porciello
- grid.417520.50000 0004 1760 5276Tumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy
| | - Ornella Franzese
- grid.6530.00000 0001 2300 0941Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
| | - Lorenzo D’Ambrosio
- grid.417520.50000 0004 1760 5276Tumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy
| | - Belinda Palermo
- grid.417520.50000 0004 1760 5276Tumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy
| | - Paola Nisticò
- grid.417520.50000 0004 1760 5276Tumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy
| |
Collapse
|
8
|
Cirulli G, Rosiello G, Mazzone E, Fossati N, Barletta F, Scuderi S, Robesti D, Gandaglia G, Toneatto L, Colandrea G, Leni R, D’Ambrosio L, Pellegrino A, Quarta L, Gallina A, Cucchiara V, Martini A, Comana S, Stabile A, Camisassa E, Dehò F, Montorsi F, Briganti A. Increased awareness of surgical outcomes improves long-term functional outcomes after robot-assisted radical prostatectomy. A prospective assessment following implementation of prospective data collection. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01250-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
9
|
Avesani G, Mazzone E, Robesti D, Gandaglia G, Stabile A, Scuderi S, Martini A, Bravi C, Rosiello G, Nocera L, Sorce G, Pellegrino F, Cirulli G, D’Ambrosio L, Necchi A, Raggi D, Marandino L, Montorsi F, Briganti A. Impact of 68Ga-PSMA PET/CT and metastasis-directed therapy on clinical recurrence in patients with biochemical recurrence after radical prostatectomy. results from a single center series. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01087-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
10
|
Merlini A, Centomo ML, Ferrero G, Chiabotto G, Miglio U, Berrino E, Giordano G, Brusco S, Pisacane A, Maldi E, Sarotto I, Capozzi F, Lano C, Isella C, Crisafulli G, Aglietta M, Dei Tos AP, Sbaraglia M, Sangiolo D, D’Ambrosio L, Bardelli A, Pignochino Y, Grignani G. DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination. Front Oncol 2022; 12:844250. [PMID: 36110934 PMCID: PMC9469659 DOI: 10.3389/fonc.2022.844250] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Accepted: 07/26/2022] [Indexed: 11/21/2022] Open
Abstract
Background Advanced and unresectable bone and soft tissue sarcomas (BSTS) still represent an unmet medical need. We demonstrated that the alkylating agent trabectedin and the PARP1-inhibitor olaparib display antitumor activity in BSTS preclinical models. Moreover, in a phase Ib clinical trial (NCT02398058), feasibility, tolerability and encouraging results have been observed and the treatment combination is currently under study in a phase II trial (NCT03838744). Methods Differential expression of genes involved in DNA Damage Response and Repair was evaluated by Nanostring® technology, extracting RNA from pre-treatment tumor samples of 16 responder (≥6-month progression free survival) and 16 non-responder patients. Data validation was performed by quantitative real-time PCR, RNA in situ hybridization, and immunohistochemistry. The correlation between the identified candidate genes and both progression-free survival and overall survival was investigated in the publicly available dataset “Sarcoma (TCGA, The Cancer Genome Atlas)”. Results Differential RNA expression analysis revealed an 8-gene signature (CDKN2A, PIK3R1, SLFN11, ATM, APEX2, BLM, XRCC2, MAD2L2) defining patients with better outcome upon trabectedin+olaparib treatment. In responder vs. non-responder patients, a significant differential expression of these genes was further confirmed by RNA in situ hybridization and by qRT-PCR and immunohistochemistry in selected experiments. Correlation between survival outcomes and genetic alterations in the identified genes was shown in the TCGA sarcoma dataset. Conclusions This work identified an 8-gene expression signature to improve prediction of response to trabectedin+olaparib combination in BSTS. The predictive role of these potential biomarkers warrants further investigation.
Collapse
Affiliation(s)
- Alessandra Merlini
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Oncology, University of Torino, Turin, Italy
| | - Maria Laura Centomo
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Oncology, University of Torino, Turin, Italy
| | - Giulio Ferrero
- Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
- Department of Computer Science, University of Torino, Turin, Italy
| | - Giulia Chiabotto
- Department of Medical Sciences, University of Torino, Turin, Italy
| | | | - Enrico Berrino
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Medical Sciences, University of Torino, Turin, Italy
| | - Giorgia Giordano
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Oncology, University of Torino, Turin, Italy
| | - Silvia Brusco
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Oncology, University of Torino, Turin, Italy
| | | | - Elena Maldi
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
| | | | | | - Cristina Lano
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Oncology, University of Torino, Turin, Italy
| | - Claudio Isella
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Oncology, University of Torino, Turin, Italy
| | - Giovanni Crisafulli
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Oncology, University of Torino, Turin, Italy
| | - Massimo Aglietta
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Oncology, University of Torino, Turin, Italy
| | - Angelo Paolo Dei Tos
- Department of Pathology, Azienda Ospedale-Università Padova, Padua, Italy
- Department of Medicine (DIMED), University of Padua School of Medicine, Padua, Italy
| | - Marta Sbaraglia
- Department of Pathology, Azienda Ospedale-Università Padova, Padua, Italy
| | - Dario Sangiolo
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Oncology, University of Torino, Turin, Italy
| | - Lorenzo D’Ambrosio
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Oncology, University of Torino, Turin, Italy
- Medical Oncology, AOU San Luigi Gonzaga, Orbassano (TO), Italy
| | - Alberto Bardelli
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Oncology, University of Torino, Turin, Italy
| | - Ymera Pignochino
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
- *Correspondence: Ymera Pignochino, ; Giovanni Grignani,
| | - Giovanni Grignani
- Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy
- *Correspondence: Ymera Pignochino, ; Giovanni Grignani,
| |
Collapse
|
11
|
Pignochino Y, Crisafulli G, Giordano G, Merlini A, Berrino E, Centomo ML, Chiabotto G, Brusco S, Basiricò M, Maldi E, Pisacane A, Leuci V, Sangiolo D, D’Ambrosio L, Aglietta M, Kasper B, Bardelli A, Grignani G. PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study. Cancers (Basel) 2021; 13:cancers13246295. [PMID: 34944915 PMCID: PMC8699802 DOI: 10.3390/cancers13246295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 12/09/2021] [Accepted: 12/13/2021] [Indexed: 11/25/2022] Open
Abstract
Simple Summary Immunotherapy has revolutionized cancer treatment, but not for all tumor types. Indeed, sarcomas are considered “immune-cold” tumors, which are relatively unresponsive to immunotherapy. One strategy to potentiate immunotherapy efficacy is to increase tumor immunogenicity, for instance by boosting the number of candidate targets (neoantigens) to be recognized by the immune system. Tumor mutational burden indicates the number of somatic mutations identified in the tumor and normalized per megabase. Tumor mutational burden is considered as an acceptable, measurable surrogate of tumor neoantigens. Here, we explored whether the combination of two DNA-damaging agents, trabectedin and olaparib, could increase tumor mutational burden in sarcomas, to prime subsequent immunotherapy. We found no variation in tumor mutational burden after trabectedin + olaparib in preclinical and clinical samples. Therefore, other aspects should be considered to increase sarcoma immunogenicity, by exploiting different pathways such as the potential modulation of the tumor microenvironment induced by trabectedin + olaparib. Abstract Drug-induced tumor mutational burden (TMB) may contribute to unleashing the immune response in relatively “immune-cold” tumors, such as sarcomas. We previously showed that PARP1 inhibition perpetuates the DNA damage induced by the chemotherapeutic agent trabectedin in both preclinical models and sarcoma patients. In the present work, we explored acquired genetic changes in DNA repair genes, mutational signatures, and TMB in a translational platform composed of cell lines, xenografts, and tumor samples from patients treated with trabectedin and olaparib combination, compared to cells treated with temozolomide, an alkylating agent that induces hypermutation. Whole-exome and targeted panel sequencing data analyses revealed that three cycles of trabectedin and olaparib combination neither affected the mutational profiles, DNA repair gene status, or copy number alterations, nor increased TMB both in homologous recombinant-defective and proficient cells or in xenografts. Moreover, TMB was not increased in tumor specimens derived from trabectedin- and olaparib-treated patients (5–6 cycles) when compared to pre-treatment biopsies. Conversely, repeated treatments with temozolomide induced a massive TMB increase in the SJSA-1 osteosarcoma model. In conclusion, a trabectedin and olaparib combination did not show mutagenic effects and is unlikely to prime subsequent immune-therapeutic interventions based on TMB increase. On the other hand, these findings are reassuring in the increasing warning of treatment-induced hematologic malignancies correlated to PARP1 inhibitor use.
Collapse
Affiliation(s)
- Ymera Pignochino
- Department of Clinical and Biological Sciences, University of Torino, 10100 Torino, Italy;
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
| | - Giovanni Crisafulli
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
- Department of Oncology, University of Torino, 10100 Torino, Italy
| | - Giorgia Giordano
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
- Department of Oncology, University of Torino, 10100 Torino, Italy
| | - Alessandra Merlini
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
- Department of Oncology, University of Torino, 10100 Torino, Italy
- Correspondence: ; Tel.: +39-0119933623
| | - Enrico Berrino
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
- Department of Medical Sciences, University of Torino, 10100 Torino, Italy;
| | - Maria Laura Centomo
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
- Department of Oncology, University of Torino, 10100 Torino, Italy
| | - Giulia Chiabotto
- Department of Medical Sciences, University of Torino, 10100 Torino, Italy;
| | - Silvia Brusco
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
- Department of Oncology, University of Torino, 10100 Torino, Italy
| | - Marco Basiricò
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
| | - Elena Maldi
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
| | - Alberto Pisacane
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
| | - Valeria Leuci
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
| | - Dario Sangiolo
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
- Department of Oncology, University of Torino, 10100 Torino, Italy
| | - Lorenzo D’Ambrosio
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
- Cardinal Massaia Hospital, 14100 Asti, Italy
| | - Massimo Aglietta
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
- Department of Oncology, University of Torino, 10100 Torino, Italy
| | - Bernd Kasper
- Sarcoma Unit, Mannheim University Medical Center, University of Heidelberg, 68167 Mannheim, Germany;
| | - Alberto Bardelli
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
- Department of Oncology, University of Torino, 10100 Torino, Italy
| | - Giovanni Grignani
- Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy; (G.C.); (G.G.); (E.B.); (M.L.C.); (S.B.); (M.B.); (E.M.); (A.P.); (V.L.); (D.S.); (L.D.); (M.A.); (A.B.); (G.G.)
| |
Collapse
|
12
|
Palmese VP, D’Ambrosio L, Aurilio M, Di Martino D, Porfidia V, Morisco A, Maisto C, Prisco A, Gaballo P, De Lauro F, Di Gennaro F, Quarto M, Lastoria S. Clinical practice implementation of personalized dosimetry in patients treated with 177Lu-DOTATATE. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00046-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
13
|
Giordano G, Merlini A, Ferrero G, Mesiano G, Fiorino E, Brusco S, Centomo ML, Leuci V, D’Ambrosio L, Aglietta M, Sangiolo D, Grignani G, Pignochino Y. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma. Cells 2021; 10:cells10112893. [PMID: 34831119 PMCID: PMC8616526 DOI: 10.3390/cells10112893] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Revised: 10/20/2021] [Accepted: 10/25/2021] [Indexed: 12/18/2022] Open
Abstract
Bone sarcomas are a group of heterogeneous malignant mesenchymal tumors. Complete surgical resection is still the cornerstone of treatment, but, in the advanced/unresectable setting, their management remains challenging and not significantly improved by target- and immuno-therapies. We focused on the tyrosine kinase Eph type-A receptor-2 (EphA2), a key oncoprotein implicated in self-renewal, angiogenesis, and metastasis, in several solid tumors and thus representing a novel potential therapeutic target. Aiming at better characterizing its expression throughout the main bone sarcoma histotypes, we investigated EPHA2 expression in the Cancer Cell Lines Encyclopedia and in public datasets with clinical annotations. looking for correlations with molecular, histopathological and patients’ features and clinical outcomes in a total of 232 osteosarcomas, 197 Ewing’s sarcomas, and 102 chondrosarcomas. We observed EPHA2 expression in bone sarcoma cell lines. We demonstrated higher EPHA2 expression in tumor tissues when compared to normal counterparts. A significant correlation was found between EPHA2 expression and Huvos grade (osteosarcoma) and with worse overall survival (dedifferentiated chondrosarcoma). Next, we characterized EPHA2 expression and activation in bone sarcoma primary tissues and in patient-derived xenografts generated in our laboratory to verify their reliability as in vivo models of osteosarcoma, Ewing’s sarcoma and chondrosarcoma. Furthermore, for the first time, we demonstrated EPHA2 expression in chondrosarcoma, suggesting its potential key role in this histotype. Indeed, we observed a significant dose-dependent antitumor effect of the EphA2-inhibitor ALW-II-41-27 in patient-derived in vitro models. In conclusion, EphA2 targeting represents a promising novel therapeutic strategy against bone sarcomas.
Collapse
Affiliation(s)
- Giorgia Giordano
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
- Department of Oncology, University of Torino, 10124 Torino, Italy
| | - Alessandra Merlini
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
- Department of Oncology, University of Torino, 10124 Torino, Italy
- Correspondence: ; Tel.: +39-0119933503
| | - Giulio Ferrero
- Department of Clinical and Biological Sciences, University of Torino, 10124 Torino, Italy;
- Department of Computer Science, University of Torino, 10124 Torino, Italy
| | - Giulia Mesiano
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
| | - Erika Fiorino
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
| | - Silvia Brusco
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
| | - Maria Laura Centomo
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
- Department of Oncology, University of Torino, 10124 Torino, Italy
| | - Valeria Leuci
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
| | - Lorenzo D’Ambrosio
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
- Cardinal Massaia Hospital, 14100 Asti, Italy
| | - Massimo Aglietta
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
- Department of Oncology, University of Torino, 10124 Torino, Italy
| | - Dario Sangiolo
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
- Department of Oncology, University of Torino, 10124 Torino, Italy
| | - Giovanni Grignani
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
| | - Ymera Pignochino
- Candiolo Cancer Institute, FPO–IRCCS Str. Prov.le 142, Km 3.95, 10060 Candiolo, Italy; (G.G.); (G.M.); (E.F.); (S.B.); (M.L.C.); (V.L.); (L.D.); (M.A.); (D.S.); (G.G.); (Y.P.)
- Department of Clinical and Biological Sciences, University of Torino, 10124 Torino, Italy;
| |
Collapse
|
14
|
Stabile A, Pellegrino F, Barletta F, Sorce G, Scuderi S, Mazzone E, Cucchiara V, Bravi C, Nocera L, Rosiello G, Cirulli G, Cannoletta D, D’Ambrosio L, Picozzi M, Fossati N, Gandaglia G, Brembilla G, Esposito A, De Cobelli F, Montorsi F, Briganti A. Optimizing the number of systematic cores during an MRI target biopsy: Preliminary results from the prospective, single center SCOT Trial (NCT 04183699). Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01241-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Palmerini E, Setola E, Grignani G, D’Ambrosio L, Comandone A, Righi A, Longhi A, Cesari M, Paioli A, Hakim R, Pierini M, Marchesi E, Vanel D, Pignochino Y, Donati DM, Picci P, Ferrari S. High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series. Cells 2020; 9:E2389. [PMID: 33142760 PMCID: PMC7692098 DOI: 10.3390/cells9112389] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Revised: 10/20/2020] [Accepted: 10/26/2020] [Indexed: 01/20/2023] Open
Abstract
Background: The evidence on high-dose ifosfamide (HD-IFO) use in patients with relapsed osteosarcoma is limited. We performed a retrospective study to analyze HD-IFO activity. Methods: Patients with osteosarcoma relapsed after standard treatment [methotrexate, doxorubicin, cisplatin +/- ifosfamide (MAP+/-I)] with measurable disease according to RECIST1.1 were eligible to ifosfamide (3 g/m2/day) continuous infusion (c.i.) days 1-5 q21d. RECIST1.1 overall response rate (ORR) (complete response (CR) + partial response (PR)), progression-free survival at 6-month (6m-PFS), duration of response (DOR), and 2-year overall survival (2y-OS) were assessed. PARP1 expression and gene mutations were tested by immunohistochemistry and next-generation sequencing. Results: 51 patients were included. ORR was 20% (1 CR + 9 PR). Median DOR was 5 months (95%CI 2-7). Median PFS, 6m-PFS, OS, and 2y-OS were 6 months (95%CI 4-9), 51%, 15 months (10-19), and 30%, respectively. A second surgical complete remission (CR2) was achieved in 26 (51%) patients. After multivariate analysis, previous use of ifosfamide (HR 2.007, p = 0.034) and CR2 (HR 0.126, p < 0.001) showed a significant correlation with PFS and OS, respectively. No significant correlation was found between outcomes and PARP1 or gene mutations. Conclusions: HD-IFO should be considered as the standard first-line treatment option in relapsed osteosarcoma and control arm of future trial in this setting.
Collapse
Affiliation(s)
- Emanuela Palmerini
- Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (E.P.); (E.S.); (A.L.); (M.C.); (A.P.); (R.H.); (M.P.); (S.F.)
| | - Elisabetta Setola
- Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (E.P.); (E.S.); (A.L.); (M.C.); (A.P.); (R.H.); (M.P.); (S.F.)
| | - Giovanni Grignani
- Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS. St. Provinciale 142, Km 3.95, 10060 Candiolo, Torino, Italy; (G.G.); (Y.P.)
| | - Lorenzo D’Ambrosio
- Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS. St. Provinciale 142, Km 3.95, 10060 Candiolo, Torino, Italy; (G.G.); (Y.P.)
| | | | - Alberto Righi
- Pathology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (A.R.); (D.V.)
| | - Alessandra Longhi
- Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (E.P.); (E.S.); (A.L.); (M.C.); (A.P.); (R.H.); (M.P.); (S.F.)
| | - Marilena Cesari
- Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (E.P.); (E.S.); (A.L.); (M.C.); (A.P.); (R.H.); (M.P.); (S.F.)
| | - Anna Paioli
- Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (E.P.); (E.S.); (A.L.); (M.C.); (A.P.); (R.H.); (M.P.); (S.F.)
| | - Rossella Hakim
- Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (E.P.); (E.S.); (A.L.); (M.C.); (A.P.); (R.H.); (M.P.); (S.F.)
| | - Michela Pierini
- Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (E.P.); (E.S.); (A.L.); (M.C.); (A.P.); (R.H.); (M.P.); (S.F.)
| | - Emanuela Marchesi
- Italian Sarcoma Group, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (E.M.); (P.P.)
| | - Daniel Vanel
- Pathology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (A.R.); (D.V.)
| | - Ymera Pignochino
- Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS. St. Provinciale 142, Km 3.95, 10060 Candiolo, Torino, Italy; (G.G.); (Y.P.)
| | - Davide Maria Donati
- Orthopedic Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy;
| | - Piero Picci
- Italian Sarcoma Group, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (E.M.); (P.P.)
| | - Stefano Ferrari
- Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; (E.P.); (E.S.); (A.L.); (M.C.); (A.P.); (R.H.); (M.P.); (S.F.)
| |
Collapse
|
16
|
Montorsi F, Bravi C, Fallara G, Rosiello G, Mazzone E, D’Ambrosio L, Gallina A, Martini A, Gandaglia G, Fossati N, Stabile A, Cucchiara V, Nocera L, Zaffuto E, Barletta F, Scuderi S, Robesti D, Rizzo A, Cannoletta D, Zito E, Longo N, Mirone V, Karakiewicz P, Briganti A. A prospective, randomized, phase 3 trial assessing the impact of Early Dorsal Venous Complex (EDVC) ligation on urinary continence recovery after robot-assisted radical prostatectomy. results of an interim analysis on early post-operative outcomes. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)35581-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
17
|
Kantidakis G, Litiere S, Neven A, Vinches M, Judson I, Schöffski P, Stacchiotti S, D’Ambrosio L, Marreaud S, Van Der Graaf W, Fiocco M, Kasper B, Gelderblom H. 1628MO A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
18
|
Grosso F, D’Ambrosio L, Zucchetti M, Ibrahim T, Tamberi S, Matteo C, Rulli E, Comandini D, Palmerini E, Baldi GG, DeCensi A, Bergaglio M, Marra D, Marchesi E, Siri G, D’Incalci M, Grignani G. Pharmacokinetics, safety, and activity of trabectedin as first‐line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group. Cancer 2020; 126:4726-4734. [DOI: 10.1002/cncr.33120] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Revised: 06/30/2020] [Accepted: 07/02/2020] [Indexed: 01/22/2023]
Affiliation(s)
- Federica Grosso
- Mesothelioma and Rare Cancer Unit Azienda Ospedaliera SS Antonio e Biagio General Hospital Alessandria Italy
| | - Lorenzo D’Ambrosio
- Division of Medical Oncology Candiolo Cancer Institute, FPO–IRCCS Candiolo Italy
- Department of Oncology University of Torino Orbassano Italy
| | - Massimo Zucchetti
- Department of Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milano Italy
| | - Toni Ibrahim
- Osteoncology and Rare Tumors Center Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy
| | | | - Cristina Matteo
- Department of Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milano Italy
| | - Eliana Rulli
- Department of Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milano Italy
| | | | | | | | - Andrea DeCensi
- Division of Medical Oncology Unit EO Ospedali Galliera Genova Italy
| | | | - Domenico Marra
- Division of Medical Oncology Unit EO Ospedali Galliera Genova Italy
| | - Emanuela Marchesi
- Division of Medical Oncology Candiolo Cancer Institute, FPO–IRCCS Candiolo Italy
| | - Giacomo Siri
- Department of Mathematics University of Genoa Genova Italy
- E.O. Ospedali GallieraScientific Directorate Genova Italy
| | - Maurizio D’Incalci
- Department of Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milano Italy
| | - Giovanni Grignani
- Division of Medical Oncology Candiolo Cancer Institute, FPO–IRCCS Candiolo Italy
| |
Collapse
|
19
|
Broto JM, Hindi N, Grignani G, Trufero JM, Redondo A, Valverde C, Pousa AL, Stacchiotti S, Palmerini E, de Alava E, Moura D, Vega HP, Collini P, Otero I, Ledesma P, Marchesi E, D’Ambrosio L, Martin JAL. IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: Results of the phase II- soft-tissue sarcoma cohort. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz283.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
D’Ambrosio L, Gaballo P, Prisco A, Di Gennaro F, Lastoria S. 321. Role of Diagnostic Reference Levels (DRLs) in Nuclear Medicine: The experience of INT Pascale in Naples. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
21
|
Raue M, Miller J, Ward C, Brady S, D’Ambrosio L, Ellis D, Felts A, Coughlin JF. STAYING SOCIAL: SOCIOEMOTIONAL CONNECTIONS AND MEANING-MAKING. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Raue
- Massachusetts Institute of Technology AgeLab, Cambridge, Massachusetts, United States
| | - J Miller
- Massachusetts Institute of Technology AgeLab, Cambridge, MA, USA
| | - C Ward
- Massachusetts Institute of Technology AgeLab, Cambridge MA, USA
| | - S Brady
- Massachusetts Institute of Technology AgeLab, Cambridge, MA, USA
| | - L D’Ambrosio
- Massachusetts Institute of Technology AgeLab, Cambridge, MA, USA
| | - D Ellis
- Massachusetts Institute of Technology AgeLab, Cambridge, MA, USA
| | - A Felts
- Massachusetts Insititute of Technology, AgeLab, Cambridge, MA, USA
| | - J F Coughlin
- Massachusetts Insititute of Technology, AgeLab, Cambridge, MA, USA
| |
Collapse
|
22
|
Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D’Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. Ther Adv Med Oncol 2018; 10:1758835918794623. [PMID: 30181783 PMCID: PMC6116078 DOI: 10.1177/1758835918794623] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2018] [Accepted: 06/05/2018] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Rechallenge with imatinib is an option in advanced gastrointestinal stromal tumor (GIST) patients following progression with standard tyrosine-kinase inhibitors (TKIs), imatinib, sunitinib and regorafenib. We retrospectively collected data from metastatic Italian GIST patients treated with imatinib resumption after progression to conventional TKIs. METHODS A total of 104 eligible advanced GIST patients, previously treated with imatinib, sunitinib and regorafenib, were collected from six referral Italian institutions. Mutational analysis was recorded and correlated with survival and response according to RECIST 1.1 or CHOI criteria. RESULTS Overall, 71 patients treated with imatinib 400 mg as rechallenge were included. Mutational status was available in all patients. The median follow up was 13 months. In patients who received a rechallenge therapy, the median time to progression (TTP) was 5.4 months [95% confidence interval (CI) 1.9-13.5] and overall survival (OS) was 10.6 months (95% CI 2.8-26.9). A correlation between mutational status, response rate, TTP and OS was not found but comparing deleted versus nondeleted KIT exon 11 patients, a significant difference was identified in terms of TTP and OS (p = 0.04 and p = 0.02, respectively). CONCLUSIONS Our retrospective data confirm that imatinib rechallenge is a reasonable option in advanced GIST. The prognostic value of the specific KIT mutations was confirmed in our series.
Collapse
Affiliation(s)
- Bruno Vincenzi
- Associate Professor in Medical Oncology,
University Campus Bio-Medico, Via Alvaro del Portillo 200, 00128, Rome,
Italy
| | - Margherita Nannini
- Department of Specialized, Experimental and
Diagnostic Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna,
Bologna
| | - Giuseppe Badalamenti
- Department of Surgical, Oncological and Oral
Science, Section of Medical Oncology, University of Palermo, Palermo,
Italy
| | | | - Elena Fumagalli
- Fondazione IRCCS Istituto Nazionale dei Tumori,
Milan, Italy
| | | | | | - Lorena Incorvaia
- Department of Surgical, Oncological and Oral
Science, Section of Medical Oncology, University of Palermo, Palermo,
Italy
| | - Marco Stellato
- Medical Oncology Department, University Campus
Bio-Medico of Rome, Rome, Italy
| | | | - Andrea Napolitano
- Medical Oncology Department, University Campus
Bio-Medico of Rome, Rome, Italy
| | - Sergio Valeri
- Department of General Surgery, University
Campus Bio-Medico of Rome, Rome, Italy
| | - Daniele Santini
- Medical Oncology Department, University Campus
Bio-Medico of Rome, Rome, Italy
| | - Giuseppe Tonini
- Medical Oncology Department, University Campus
Bio-Medico of Rome, Rome, Italy
| | | | | | - Maria Abbondanza Pantaleo
- Department of Specialized, Experimental and
Diagnostic Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna,
Bologna
| |
Collapse
|
23
|
Tiberi S, D’Ambrosio L, Centis R, Migliori G. Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis? Int J Infect Dis 2017; 65:133-134. [DOI: 10.1016/j.ijid.2017.10.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Accepted: 10/31/2017] [Indexed: 10/18/2022] Open
|
24
|
Orlando S, Callovini G, Altavilla B, D’Ambrosio L, Iasevoli F. Psychiatric patients show different coping styles during aggression compared to controls. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.1378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionAggression and violence are common phenomena, potentially experienced by everyone.ObjectivesTo demonstrate that coping patterns to face aggression and violence may exhibit differential group features.AimsTo find differences in coping styles during moments of high aggression in psychiatric patients compared to non-affected controls.MethodsWe evaluated 34 outpatients from the section of psychiatry of university Federico II of Naples by two psychometric scales: AQ to evaluate aggression levels and Brief-COPE for coping patterns. Outcomes were compared with that of 34 non-affected controls, recruited from the university student population. Pearson's correlation was used to find relationships between aggression levels and coping skills in these two groups.ResultsWe found significant differences between groups in multiple scale items and in the correlation measures, e.g. the use of expression was completely reversed in this two samples according to aggression levels.ConclusionsThese results show that aggression is experienced differentially and with different coping styles by psychiatric patients compared to non-affected controls.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
25
|
Marchesi E, Cagnazzo C, Quattrini I, Leopardi MP, Villa C, Grignani G, D’Ambrosio L, Stacchiotti S, Casali PG, Picci P. How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. Clin Sarcoma Res 2017; 7:4. [PMID: 28261443 PMCID: PMC5329913 DOI: 10.1186/s13569-017-0068-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Accepted: 02/07/2017] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND The Italian Sarcoma Group (ISG) is a nonprofit group of professionals established in 1997 aimed to improve the quality of care and promote the independent research in sarcomas. The increased regulatory requirements, the chance to increase the number of trials with other cooperative groups and an interest from pharmaceutical companies in supporting independent research, generated the need of an internal service for research management. METHODS AND RESULTS In 2010, ISG implemented in its organization a Clinical Trial Unit (CTU). The CTU was appointed to fully manage Clinical Trial Operations, to guarantee regulation compliance and provide a central support to the investigators, fostering a collaboration both at national and international level. In 2016 ISG promoted 25 studies in about 120 centers, with a fivefold increase in the last 5 years: 68% were interventional and 32% observational. Nine of the 17 interventional studies (52%) were supported by pharmaceutical companies, while 4 (24%) were funded by European Commission within specific projects on sarcomas and 4 (24%) were supported by the ISG itself. CONCLUSION The contribution of ISG researchers to the international community was striking from the earliest years of the ISG creation. The challenges of the regulatory clinical research scenario, which imposes solid and hard-fast methodology with deep knowledge and expertise, highlighted the need to identify qualified and dedicated experts able to run and follow the multifaceted aspects of trials. Our analysis demonstrated how this model has led to a growth in competitiveness of the group. The collaboration between clinicians and CTU made possible to support the research with high scientific and ethical standards and to increase the number of trials, sites and overall enrolled patients. The reduced time for approvals, the continuous support to sites, the increased speed in data collection and analysis make the ISG research attractive for pharmaceutical industries, despite the problems that have characterized the independent research in the last years. The ability to fully manage and oversight Clinical Operations and the high quality of delivered services, have led the ISG to be recognized as a reliable partner and coordinator within the international sarcoma networks.
Collapse
Affiliation(s)
- Emanuela Marchesi
- Italian Sarcoma Group, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
| | - Celeste Cagnazzo
- Division of Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
| | - Irene Quattrini
- Italian Sarcoma Group, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
| | | | - Chiara Villa
- Adult Mesenchymal Tumour and Rare Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - Giovanni Grignani
- Division of Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
| | - Lorenzo D’Ambrosio
- Division of Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
| | - Silvia Stacchiotti
- Adult Mesenchymal Tumour and Rare Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - Paolo Giovanni Casali
- Adult Mesenchymal Tumour and Rare Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - Piero Picci
- Laboratory of Experimental Oncology, Orthopedic Rizzoli Institute, Bologna, Italy
| |
Collapse
|
26
|
Leuci V, Casucci M, Grignani G, Rotolo R, Vigna E, Gammaitoni L, Mesiano G, D’Ambrosio L, Aglietta M, Bondanza A, Sangiolo D. Abstract 2298: Cytokine-induced killer cells redirected with anti-CD44v6 chimeric antigen receptor against soft tissue sarcomas. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-2298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose of our study is to explore the anti-sarcoma activity of cytokine-induced killer (CIK) cells engineered with a chimeric antigen receptor (CAR) against the isoform variant 6 of adhesive receptor CD44 (CD44v6). CD44v6 may be an ideal target for immunotherapy as it is a tumor-promoting antigen, associated with the metastatic process and tumor initiating cells. Advanced and metastatic soft tissue sarcomas (STS) are currently incurable and in great need for new therapeutic strategies.
CIK cells are ex vivo expanded T lymphocytes endowed with MHC-independent antitumor activity.
CIK cells are active against STS (Sangiolo et al. Cancer Research 2014) but their function decreases at low effector/target (E/T) ratios with limitations in clinical perspective. We hypothesized that CIK cells may be effective candidates for CAR-based strategies, considering their intense ex vivo expansibility and innate antitumor activity.
Experimental procedures and results. CIK cells were expanded from 9 STS patients and engineered with a lentiviral vector encoding for anti-CD44v6 CAR containing a CD28 signaling domain (Casucci et al, Blood 2013) and the HSV-TK suicide switch. Tumor killing was assessed in vitro against 10 STS (undifferentiated pleomorphic n = 5; Liposarcoma n = 2; Fibrosarcoma n = 1; GIST n = 2), in 2 cases STS targets were autologous.
All 10 STS expressed CD44v6 (Relative Fluorescence Intensity = 4, SE = 1). Mean transduction efficiency was 60% (SE = 6%). Expansion rates and phenotype of CAR-CIK were comparable with unmodified controls (CD3+CD56+ = 50%; CD8 = 66%; NKG2D = 85%).
Anti-CD44v6 CAR-CIK cells efficiently killed STS in vitro. Mean tumor-specific killing, at low E/T ratios, was significantly higher compared with unmodified CIK cells: 98% vs 84% (E/T = 10:1, p>0.05), 89% vs 41% (E/T = 1:1, p = 0.0001), 65% vs 26% (E/T = 1:4 p = 0.0001).
In vitro treatment with Ganciclovir (10 μM) significantly inhibited tumor killing activity of CAR-CIK from 70% to 10% (E/T 1:1, n = 3, p = 0.008).
Blocking experiments (n = 2) with anti-CD44v6 antibody against the same epitope recognized by the CAR (VFF-18) decreased tumor-specific killing from 96% to 43% (E/T = 1:1) and 27% (E/T = 1:2). Adoptive infusion of anti-CD44v6 CAR-CIK cells significantly delayed tumor growth (p = 0.01) and reduced proliferative index (p = 0.001) of established subcutaneous fibrosarcoma xenografts in NOD/SCID mice (n = 3) compared to untreated controls (n = 3) without any sign of toxicity.
Conclusions. Ours is the first report of CAR-engineered CIK cells against solid tumors. This approach significantly potentiates the innate tumor killing ability of CIK cells with a new redirected antitumor specificity. CIK cells may be appealing alternative candidates to conventional T cells for future CAR-based strategies against solid tumors. Our findings support CD44v6 as a valuable target for adoptive cell therapies against currently incurable sarcomas.
Citation Format: Valeria Leuci, Monica Casucci, Giovanni Grignani, Ramona Rotolo, Elisa Vigna, Loretta Gammaitoni, Giulia Mesiano, Lorenzo D’Ambrosio, Massimo Aglietta, Attilio Bondanza, Dario Sangiolo. Cytokine-induced killer cells redirected with anti-CD44v6 chimeric antigen receptor against soft tissue sarcomas. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2298.
Collapse
Affiliation(s)
- Valeria Leuci
- 1University of Torino, Department of Oncology, Candiolo Cancer Institute IRCCS, Candiolo, Italy
| | - Monica Casucci
- 2San Raffaele Hospital Scientific Institute, Innovative Immunotherapies Unit, Milan, Italy
| | | | - Ramona Rotolo
- 1University of Torino, Department of Oncology, Candiolo Cancer Institute IRCCS, Candiolo, Italy
| | - Elisa Vigna
- 1University of Torino, Department of Oncology, Candiolo Cancer Institute IRCCS, Candiolo, Italy
| | | | | | - Lorenzo D’Ambrosio
- 1University of Torino, Department of Oncology, Candiolo Cancer Institute IRCCS, Candiolo, Italy
| | - Massimo Aglietta
- 1University of Torino, Department of Oncology, Candiolo Cancer Institute IRCCS, Candiolo, Italy
| | - Attilio Bondanza
- 2San Raffaele Hospital Scientific Institute, Innovative Immunotherapies Unit, Milan, Italy
| | - Dario Sangiolo
- 1University of Torino, Department of Oncology, Candiolo Cancer Institute IRCCS, Candiolo, Italy
| |
Collapse
|
27
|
Affiliation(s)
- L D’Ambrosio
- WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy
| | - R Centis
- WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy
| | - A Spanevello
- Universita` degli Studi dell’Insubria, Varese, Italy
- WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy
| | - G B Migliori
- WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy
| |
Collapse
|